Tofacitinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4224 publications

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews
Published: June 23, 2026

Adjunctive Tofacitinib in Moderate-To-Severe Bullous Pemphigoid: A Single-Center Prospective Cohort Study.

Adjunctive Tofacitinib in Moderate-To-Severe Bullous Pemphigoid: A Single-Center Prospective Cohort Study.

Journal: American journal of therapeutics
Published: June 16, 2026

Tofacitinib for Pigmented Purpuric Dermatoses: Subtype-Specific Therapeutic Responses and Clinical Implications.

Tofacitinib for Pigmented Purpuric Dermatoses: Subtype-Specific Therapeutic Responses and Clinical Implications.

Journal: American journal of therapeutics
Published: June 15, 2026

Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.

Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.

Journal: Current opinion in pediatrics
Published: June 04, 2026

TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review.

TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: June 02, 2026

Detection of hard electrophilic reactive metabolites formed from alicyclic amines using glutathione trapping.

Detection of hard electrophilic reactive metabolites formed from alicyclic amines using glutathione trapping.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 02, 2026

Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors.

Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors.

Journal: Expert opinion on pharmacotherapy
Published: May 19, 2026

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Journal: Internal medicine (Tokyo, Japan)
Published: May 17, 2026

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review.

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review.

Journal: Cureus
Published: May 15, 2026

Adenosine deaminase acting on RNA1 mutation in chilblain lupus treated with tofacitinib.

Adenosine deaminase acting on RNA1 mutation in chilblain lupus treated with tofacitinib.

Journal: JAAD case reports
Published: May 13, 2026

Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors.

Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors.

Journal: Journal of Crohn's & colitis
Published: May 12, 2026

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo.

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo.

Journal: Indian journal of dermatology
Published: May 11, 2026
Showing 1-12 of 4,224

Last Updated: 06/30/2026